IN THE CLAIMS

Please cancel claims 1-21 without prejudice and add the following claims:

1-21. (Canceled)

22. A pharmaceutical composition comprising a therapeutically effective amount of unitary doses of viral particles of recombinant adenoviral vectors, wherein the adenoviral vectors comprise an adenoviral genome replaced with a therapeutic gene or DNA sequence regulated by a ubiquitous promoter, a tissue-specific promoter, or a combination thereof, that encodes for one or more therapeutic proteins for the treatment of fibrotic disorders in organs and a pharmaceutically compatible carrier.

23. The pharmaceutical composition of claim 22, wherein the unitary dose is about 10^7-10^{14} viral particles.

24. A method of treating fibrotic disorders in a patient, comprising:

preparing a recombinant adenoviral vector containing a therapeutic gene or DNA sequence;

delivering the recombinant adenoviral vector by an administrative route to an organ; and

generating therapeutic proteins in the organ from the recombinant adenoviral vector to treat the fibrotic disorders.

25. The method of claim 24, wherein the administrative route is endovenous.

26. The method of claim 24, wherein the organ is selected from liver, lung, heart, kidney, skin, hypertrophic scars, and combinations thereof.

27. The method of claim 24, wherein the fibrotic disorders are hepatic fibrosis, pulmonary fibrosis, renal fibrosis, heart fibrosis, keloids, hypertrophic scars, or combinations thereof.